Genetic and Environmental Risk Factors for PSP
Genetic and Environmental Risk Factors for PSP
批准号:
7870302
负责人:
Irene Litvan
金额:
$43.37万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2006
资助国家:
美国
项目状态:
已结题
起止时间:
2006-07-15 至 2013-06-30
关键词:
AddressAffectAgeAlzheimer&aposs DiseaseAnimal ModelAreaBrainCarbon DisulfideCarbon MonoxideCase-Control StudiesCellsChemicalsChronicClinicalCollaborationsComplexCoupledDNADeltastabDevelopmentDiagnosisDiseaseEnrollmentEnvironmentEnvironmental ExposureEnvironmental Risk FactorEpidemiologistEtiologyExposure toFamilyFirst Degree RelativeFutureGenderGene MutationGenesGeneticGenetic PolymorphismGenetic VariationGenotypeGoalsHaplotypesHerbicidesHypertensionInjuryInterventionKnowledgeLeadManganeseMetabolismMethodologyMitochondriaMovement DisordersMulticenter StudiesMutationNational Institute of Neurological Disorders and StrokeNeurodegenerative DisordersOccupationalOrganic solvent productOther GeneticsParkin genePathogenesisPatientsPatternPesticidesPlayProgressive Supranuclear PalsyQuestionnairesRecording of previous eventsResearchResearch InfrastructureResearch PersonnelResourcesRiskRisk FactorsRoleRotenoneSamplingSecondary Parkinson DiseaseSeriesSeverity of illnessSiteSpecialistStructureSuggestionSymptomsTauopathiesTestingTetrahydroisoquinolinesTransition ElementsTraumatic Brain InjuryVariantWorkacetogeninalpha synucleinbasecarbamate insecticidecase controldesigndopaminergic neuronenvironmental chemical exposuregene interactiongenetic risk factorhigh riskinhibitor/antagonistleucine-rich repeat kinase 2multidisciplinaryneurotoxicparkin gene/proteinprogramspromoterprophylacticrepositorysodium arsenitestemtau Proteinstau-1
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): Progressive supranuclear palsy (PSP) is a sporadic tauopathy with unknown cause. The H1 tau haplotype is implicated in its etiology; however, it is also present in 60% of normal controls. This, coupled with late symptom onset, indicates that genetics alone does not cause PSP. Support for the environmental factor hypothesis stems from animal models and the observed association between PSP and exposure to mitochondrial complex I inhibitors (i.e., acetogenins), which are neurotoxic to dopaminergic neurons. Impaired metabolism in PSP mitochondria and oxidative injury in affected brain areas also support this hypothesis. Hence, genes and environment may both play a role either alone or through their interactions. This application will determine: 1) if there is an association between PSP and the HI/HI genotype, specific HI sub-haplotypes, alpha-synuclein polymorphisms or parkin gene deficits, or if there are gene-gene interactions; 2) if there is an association between PSP occupational and/or environmental chemical exposures functionally or structurally similar to rotenone/acetogenins; and 3) if hypertension or traumatic brain injury prior to symptom-onset is associated with PSP. To disentangle the complex etiology of PSP, this case-control multicenter study involves 500 PSP cases, 500 age/gender matched primary controls, and 500 secondary controls for genetic confirmation. Previous case-control studies have been inconclusive because of limitations in size, scope, or structure. This is the first adequately powered series of PSP cases with matched controls that has the necessary infrastructure to address our hypotheses and explore gene-environmental interactions. As a result, it will help resolve controversies concerning the cause(s) of PSP and will stimulate new avenues of pathogenesis research and prophylactic therapies. Understanding the etiology of PSP may also help explain the causes of other tauopathies such as Alzheimer's disease. This multidisciplinary team of movement disorder specialists, epidemiologists, geneticists, biostatisticians, industrial hygienist and toxicologist is well suited to unravel the complex etiology of PSP. The use of the NINDS cell repository for genetic banking will also allow DNA sample sharing with other investigators.
期刊论文(31)
专著(0)
科研奖励(0)
会议论文
登录
查看更多内容
Primary health care providers' knowledge gaps on Parkinson's disease.
初级卫生保健提供者对帕金森病的知识差距。
DOI:
10.1080/03601277.2013.767599
发表时间:
2013
期刊:
Educational gerontology
影响因子:
1.5
作者:
[Thompson,MeganR, Stone,RamonaF, DanOchs,V, Litvan,Irene]
通讯作者:
Litvan,Irene
DOI:
10.1002/mds.25850
发表时间:
2014-04-15
期刊:
MOVEMENT DISORDERS
影响因子:
8.6
作者:
[Burn, David, Weintraub, Daniel, Ravina, Bernard, Litvan, Irene]
通讯作者:
Litvan, Irene
DOI:
10.1016/s1353-8020(09)70787-4
发表时间:
2009-12
期刊:
Parkinsonism & related disorders
影响因子:
4.1
作者:
[C. Adler]
通讯作者:
C. Adler
Prominent tongue and jaw tremor in a patient with probable Progressive Supranuclear Palsy.
可能患有进行性核上性麻痹的患者出现明显的舌头和下颌震颤。
DOI:
10.1002/mdc3.12562
发表时间:
2018
期刊:
Movement disorders clinical practice
影响因子:
4
作者:
[Shoeibi,Ali, Litvan,Irene]
通讯作者:
Litvan,Irene
Toward magnetic resonance imaging biomarkers for progressive supranuclear palsy and multisystem atrophy.
寻找进行性核上性麻痹和多系统萎缩的磁共振成像生物标志物。
DOI:
10.1002/mds.25196
发表时间:
2012
期刊:
Movement disorders : official journal of the Movement Disorder Society
影响因子:
--
作者:
[Sauvaget,Frederic, Litvan,Irene]
通讯作者:
Litvan,Irene
共 9 条
Real-Time L-Dopa Monitoring for Improved Management of Parkinson Disease
-
批准号:10056836
-
项目类别:
-
资助金额:$43.39万
-
财政年份:2020
-
负责人:Irene Litvan
-
依托单位:
Second International Brainstorming Meeting on Parkinson Disease: Nosology
-
批准号:7485398
-
项目类别:
-
资助金额:$1.25万
-
财政年份:2008
-
负责人:Irene Litvan
-
依托单位:
Genetic and Environmental Risk Factors for PSP
-
批准号:7096316
-
项目类别:
-
资助金额:$62.89万
-
财政年份:2006
-
负责人:Irene Litvan
-
依托单位:
Genetic and Environmental Risk Factors for PSP
-
批准号:7631302
-
项目类别:
-
资助金额:$55.06万
-
财政年份:2006
-
负责人:Irene Litvan
-
依托单位:
Genetic and Environmental Risk Factors for PSP
-
批准号:7457789
-
项目类别:
-
资助金额:$54.31万
-
财政年份:2006
-
负责人:Irene Litvan
-
依托单位:
Genetic and Environmental Risk Factors for PSP
-
批准号:7259458
-
项目类别:
-
资助金额:$56.71万
-
财政年份:2006
-
负责人:Irene Litvan
-
依托单位:
海外基金